A Milestone Moment: FDA Approves Addyi® for Hypoactive Sexual Desire Disorder in Postmenopausal Women
December 17, 2025
Brand Name :
vivjoa
Synonyms :
Oteseconazole
Class :
Azole antifungal
Dosage Forms & Strengths
150mg
Only Oteseconazole dosage regimen:
Day 1:600mg orally in a single dose
Day 2:450mg orally in a single dose
Day 14:150mg orally every week for 11 weeks
Oteseconazole and fluconazole dosage regimen:
Day 1,4 and 7: Fluconazole-150mg orally in a single dose
Day 14 to 20: Oteseconazole-150mg orally every day for seven days
Beginning on day 28: Oteseconazole-150mg orally every week for 11 weeks
may increase the serum concentration
may enhance the serum concentration of BRCP/ABCG2 inhibitors
may enhance the serum concentration of BRCP/ABCG2 inhibitors
may enhance the serum concentration of BRCP/ABCG2 inhibitors
may enhance the serum concentration of BRCP/ABCG2 inhibitors
may enhance the serum concentration of BRCP/ABCG2 inhibitors
may enhance the serum concentration of BRCP/ABCG2 inhibitors
may enhance the serum concentration of BRCP/ABCG2 inhibitors
Frequency defined:
1-10%
Nausea
Hot flush
Menorrhagia
Vulvovaginal irritation
Headache
Dyspepsia
Dysuria
Metrorrhagia
Elevated serum creatinine phosphokinase≥10X ULN
<1%
Allergic dermatitis
Pregnancy consideration:
US FDA pregnancy category: Not assigned
Lactation: In lactating women, the usage is contraindicated
Pregnancy category:
Category A: well-controlled and Satisfactory studies show no risk to the fetus in the first or later trimester.
Category B: there was no evidence of risk to the fetus in animal studies, and there were not enough studies on pregnant women.
Category C: there was evidence of risk of adverse effects in animal reproduction studies, and no adequate evidence in human studies must take care of potential risks in pregnant women.
Category D: adequate data available with sufficient evidence of human fetal risk from various platforms, but despite the potential risk, and used only in emergency cases for potential benefits.
Category X: Drugs listed in this category outweigh the risks over benefits. Hence these categories of drugs need to be avoided by pregnant women.
Category N: There is no data available for the drug under this category
Patient information leaflet
Generic Name: Oteseconazole
Pronounced: (oh-TES-e-KON-a-zole)
Why do we use Oteseconazole?
It is used to treat vulvovaginal candidiasis, which is recurrent in females with less reproductive potential